Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch

US FDA Cleared KRAS G12C Inhibitor For Second-Line NSCLC

Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.

Red paper lungs on wood background
Lumakras is approved for second line or later KRAS G12C-mutated non-small cell lung cancer • Source: Alamy

Amgen, Inc. has secured a several month lead with its newly approved Lumakras (sotorasib) as the only KRAS G12C inhibitor available in the US before its likely first competitor, adagrasib from Mirati Therapeutics, Inc., hits the market. Even so, Amgen executive vice president of global commercial operations Murdo Gordon told Scrip that the company still faces the tough challenge of launching its new drug during the COVID-19 pandemic.

The US Food and Drug Administration approved Lumakras (sotorasib) on 28 May for the treatment of KRAS G12C-mutated locally advanced...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip